Today, the FDA approved Oxytrol for Women, a patch containing oxybutynin that treats overactive bladder, for over-the-counter sale to women ages 18 and older.
Today, the FDA approved Oxytrol for Women, a patch containing oxybutynin that treats overactive bladder, for over-the-counter sale to women ages 18 and older. Men still need a prescription for the drug.
Oxybutynin is an anticholinergic agent that treats overactive bladder by relaxing the bladder muscles and decreasing muscle spasms. This is the first time an anticholinergic agent has been approved for OTC sale.
The approval comes in spite of an FDA advisory committee’s November vote recommending against OTC availability. Concerns cited include patients’ ability to self-select, and the possibility of men using the product off-label.
Merck, the company that will manufacture Oxytrol for Women, did not seek approval for OTC use in men, because studies showed that men were not reliably able to determine whether the drug was the appropriate treatment for their urinary problems. In men, incorrect diagnosis of urinary issues could delay the detection of prostate cancer.
Reduced subsequent births reported after severe maternal morbidity
November 26th 2024Women experiencing severe maternal morbidity during their first pregnancy face significantly lower odds of subsequent births, emphasizing the need for personalized reproductive counseling and ongoing monitoring.
Read More
Maternal sFLT1 and EDN1 linked to late-onset preeclampsia
November 25th 2024A new study highlights the association of maternal soluble Fms-like tyrosine kinase 1 and endothelin 1 with preeclampsia severity, offering insights into the pathogenesis of early- and late-onset forms of the condition.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More